UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer

World journal of gastroenterology : WJG, 2016-08, Vol.22 (31), p.6987-7005

2016

Volltextzugriff (PDF)

Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma

Annals of surgery, 2020-06, Vol.271 (6), p.1137-1147

2020

Volltextzugriff (PDF)

Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer

Scientific reports, 2017-08, Vol.7 (1), p.7931-8, Article 7931

2017

Volltextzugriff (PDF)

Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes

Anti-cancer agents in medicinal chemistry, 2022-01, Vol.22 (7), p.1278-1285

2022

Volltextzugriff (PDF)

New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?

OncoTargets and therapy, 2016-01, Vol.9, p.6065-6074

2016

Volltextzugriff (PDF)

Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: A systematic review

World journal of gastroenterology : WJG, 2014-05, Vol.20 (20), p.6081-6091

2014

Volltextzugriff (PDF)

Circulating microRNAs as dynamic biomarkers of response to treatment with FOLFIRINOX combination therapy in advanced pancreatic ductal adenocarcinoma

The Lancet (British edition), 2017-02, Vol.389, p.S68-S68

2017

Volltextzugriff (PDF)

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC

British journal of cancer, 2018-03, Vol.118 (6), p.820-824

2018

Volltextzugriff (PDF)

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial

Journal of hepatology, 2018-08, Vol.69 (2), p.353-358

2018

Volltextzugriff (PDF)

Mortality in an Italian nursing home during COVID-19 pandemic: correlation with gender, age, ADL, vitamin D supplementation, and limitations of the diagnostic tests

Aging (Albany, NY.), 2020-12, Vol.12 (24), p.24522-24534

2020

Volltextzugriff (PDF)

First‐line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors

International journal of cancer, 2016-08, Vol.139 (4), p.938-945

2016

Volltextzugriff (PDF)

Abstract 3649: Circulating microRNA-181a monitors response to FOLFIRINOX chemotherapy in pancreatic ductal adenocarcinoma

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3649-3649

2018

Volltextzugriff (PDF)

Anti-HER agents in gastric cancer: from bench to bedside

Nature reviews. Gastroenterology & hepatology, 2011-07, Vol.8 (7), p.369-383

2011

Volltextzugriff (PDF)

Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data

Journal of experimental & clinical cancer research, 2015-12, Vol.34 (155), p.156-156, Article 156

2015

Volltextzugriff (PDF)

Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'

British journal of cancer, 2016-05, Vol.114 (11), p.e8-e8

2016

Volltextzugriff (PDF)

Prognostic role of neutrophil-to-lymphocyte ratio (NLR) dynamics during first-line FOLFOXIRI in advanced pancreatic cancer (aPC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e15754-e15754

2017

Volltextzugriff (PDF)

Correlation of early tumor shrinkage (ETS) and depth of response (DoR) with resectability in patients (pts) with unresectable locally advanced pancreatic cancer (LAPC) undergoing primary treatment with FOLFOXIRI

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e15777-e15777

2017

Volltextzugriff (PDF)

Variations of circulating KRAS amount as a biomarker to monitor chemotherapy response in pancreatic cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e15794-e15794

2017

Volltextzugriff (PDF)

Second-line (SL) chemotherapy containing oxaliplatin (OXA) in metastatic pancreatic cancer (PC): Whom should we trust?

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e15719-e15719

2017

Volltextzugriff (PDF)

Association of PD-L1 mRNA levels in plasma-derived exosomes with response to nivolumab and pembrolizumab in melanoma and NSCLC

Journal of clinical oncology, 2018-02, Vol.36 (5_suppl), p.210-210

2018

Volltextzugriff (PDF)

Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature

Future oncology (London, England), 2016-04, Vol.12 (7), p.901-908

2016

Volltextzugriff (PDF)

Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients

Oncology, 2016-01, Vol.91 (6), p.311-316

2016

Volltextzugriff (PDF)

Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.344-344

2017

Volltextzugriff (PDF)

Oxaliplatin in pre-treated patients: maybe not the match point?

Translational cancer research, 2017-02, Vol.6 (S1), p.S163-S167

2017

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(40)

Sprache

Englisch
(40)

Erscheinungsjahr

n.n

Thema

Science & Technology
(27)
Life Sciences & Biomedicine
(26)
Humans
(21)
Oncology
(17)
Chemotherapy
(12)
Female
(11)
Male
(11)
Aged
(10)
Metastasis
(9)
Middle Aged
(9)
Treatment Outcome
(9)
Pancreatic Cancer
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Cancer
(7)
Gastroenterology & Hepatology
(7)
Adult
(6)
Antineoplastic Agents - Therapeutic Use
(6)
Care And Treatment
(6)
Patients
(6)
Prognosis
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer

Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma

Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer

Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes

New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?

Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: A systematic review

Circulating microRNAs as dynamic biomarkers of response to treatment with FOLFIRINOX combination therapy in advanced pancreatic ductal adenocarcinoma

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial

Mortality in an Italian nursing home during COVID-19 pandemic: correlation with gender, age, ADL, vitamin D supplementation, and limitations of the diagnostic tests

First‐line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors

Abstract 3649: Circulating microRNA-181a monitors response to FOLFIRINOX chemotherapy in pancreatic ductal adenocarcinoma

Anti-HER agents in gastric cancer: from bench to bedside

Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data

Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'

Prognostic role of neutrophil-to-lymphocyte ratio (NLR) dynamics during first-line FOLFOXIRI in advanced pancreatic cancer (aPC)

Correlation of early tumor shrinkage (ETS) and depth of response (DoR) with resectability in patients (pts) with unresectable locally advanced pancreatic cancer (LAPC) undergoing primary treatment with FOLFOXIRI

Variations of circulating KRAS amount as a biomarker to monitor chemotherapy response in pancreatic cancer

Second-line (SL) chemotherapy containing oxaliplatin (OXA) in metastatic pancreatic cancer (PC): Whom should we trust?

Association of PD-L1 mRNA levels in plasma-derived exosomes with response to nivolumab and pembrolizumab in melanoma and NSCLC

Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature

Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients

Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial

Oxaliplatin in pre-treated patients: maybe not the match point?

Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol

Suchergebnisse filtern